PL2033629T3 - Stała kompozycja farmaceutyczna zawierająca walsartan - Google Patents

Stała kompozycja farmaceutyczna zawierająca walsartan

Info

Publication number: PL2033629T3
Authority: PL; Poland
Prior art keywords: valsartan; pharmaceutical composition; solid pharmaceutical; solid; composition
Prior art date: 2004-12-24

Application number

PL08165631T

Other languages

English (en)

Inventor

Miha Vrbinc

Vovk Janika Slanc

Marija Rangus

Silvo Zupancic

Franci Bevec

Lidija Cernosa

Original Assignee

Krka

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-24

Filing date

2005-12-23

Publication date

2013-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35966966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2033629(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-12-24 Priority claimed from EP04030782A external-priority patent/EP1674080A1/en

2005-12-23 Application filed by Krka filed Critical Krka

2013-04-30 Publication of PL2033629T3 publication Critical patent/PL2033629T3/pl

Links

239000004072 C09CA03 - Valsartan Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
239000007787 solid Substances 0.000 title 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title 1
229960004699 valsartan Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL08165631T 2004-12-24 2005-12-23 Stała kompozycja farmaceutyczna zawierająca walsartan PL2033629T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP04030782A EP1674080A1 (en)	2004-12-24	2004-12-24	Solid pharmaceutical composition comprising valsartan
EP05004433		2005-03-01
EP08165631A EP2033629B1 (en)	2004-12-24	2005-12-23	Solid pharmaceutical composition comprising valsartan
EP20050824409 EP1833464A1 (en)	2004-12-24	2005-12-23	Solid pharmaceutical composition comprising valsartan

Publications (1)

Publication Number	Publication Date
PL2033629T3 true PL2033629T3 (pl)	2013-04-30

Family

ID=35966966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08165631T PL2033629T3 (pl)	2004-12-24	2005-12-23	Stała kompozycja farmaceutyczna zawierająca walsartan

Country Status (16)

Country	Link
US (1)	US20080102120A1 (pl)
EP (2)	EP2033629B1 (pl)
CN (1)	CN101087589B (pl)
AU (1)	AU2005318365B2 (pl)
CA (1)	CA2592091A1 (pl)
DK (1)	DK2033629T3 (pl)
EA (2)	EA015108B1 (pl)
ES (1)	ES2397552T3 (pl)
HR (1)	HRP20130033T1 (pl)
ME (1)	ME01453B (pl)
NO (1)	NO20073889L (pl)
PL (1)	PL2033629T3 (pl)
PT (1)	PT2033629E (pl)
RS (1)	RS52607B (pl)
SI (1)	SI2033629T1 (pl)
WO (1)	WO2006066961A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1897537A1 (en) *	2006-09-04	2008-03-12	Novartis AG	Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) *	2006-09-04	2008-12-04	Novartis Ag	Composicion farmaceutica que comprende valsartan
WO2008076780A2 (en) *	2006-12-14	2008-06-26	Isp Investments Inc.	Amorphous valsartan and the production thereof
TR200703568A1 (tr) *	2007-05-24	2008-07-21	Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket�	Valsartan formülasyonları
GB0715628D0 (en) *	2007-08-10	2007-09-19	Generics Uk Ltd	Solid valsartan composition
WO2009113091A2 (en) *	2008-01-24	2009-09-17	Usv Limited	Pharmaceutical compositions comprising valsartan
WO2010104485A2 (en) *	2009-03-11	2010-09-16	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Valsartan formulations
SI2536396T1 (sl)	2010-02-16	2017-01-31	KRKA, tovarna zdravil, d.d.,Novo mesto	Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
CN102119912A (zh) *	2011-01-25	2011-07-13	南京白敬宇制药有限责任公司	一种非水溶性药物缓释制剂的制备方法
CN102204907A (zh) *	2011-03-31	2011-10-05	北京赛科药业有限责任公司	一种含缬沙坦的药物组合物及其制备方法
WO2013098578A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan
CN103599084B (zh) *	2013-11-22	2018-10-30	威海迪素制药有限公司	一种降压组合物
KR101545268B1 (ko) *	2015-02-05	2015-08-20	보령제약 주식회사	정제 및 이의 제조방법
CN104887640B (zh) *	2015-06-30	2017-12-19	昆明医科大学	一种含有缬沙坦的固体药物组合物
US20210267908A1 (en) *	2020-03-02	2021-09-02	Mankind Pharma Ltd.	Pharmaceutical compositions of rivaroxaban
CN112098408B (zh) *	2020-09-14	2022-12-09	湖北亿纬动力有限公司	一种羧甲基纤维素钠溶解效果的检测方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0443983B1 (de)	1990-02-19	1996-02-28	Ciba-Geigy Ag	Acylverbindungen
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
NZ511938A (en)	1998-12-23	2004-02-27	Novartis Ag	Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor
US6294192B1 (en) *	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6211217B1 (en) *	1999-03-16	2001-04-03	Novartis Ag	Method for reducing pericardial fibrosis and adhesion formation
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
PE20020082A1 (es) *	2000-04-12	2002-02-21	Novartis Ag	Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)
US6499984B1 (en) *	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation
NZ522953A (en)	2000-06-22	2005-10-28	Novartis Ag	Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
CZ303389B6 (cs) *	2000-07-19	2012-08-29	Novartis Ag	Sul valsartanu a farmaceutický prípravek obsahující tuto sul
US20030152622A1 (en) *	2001-10-25	2003-08-14	Jenny Louie-Helm	Formulation of an erodible, gastric retentive oral diuretic
DE60315795T2 (de)	2002-01-17	2008-06-05	Novartis Ag	Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
CN1726030A (zh) *	2002-12-18	2006-01-25	诺瓦提斯公司	缬沙坦与cox－2抑制剂的组合
DE602004013405T2 (de)	2003-03-17	2009-05-07	Teva Pharmaceutical Industries Ltd.	Polymorphe formen von valsartan
EP1618097A1 (en) *	2003-04-21	2006-01-25	Teva Pharmaceutical Industries Ltd	Process for the preparation of valsartan
WO2004094391A2 (en)	2003-04-21	2004-11-04	Teva Pharmaceutical Industries Ltd.	Process for the preparation of valsartan and intermediates thereof
US7569612B1 (en) *	2006-08-21	2009-08-04	Mutual Pharmaceutical Company, Inc.	Methods of use of fenofibric acid

2005
- 2005-12-23 EA EA200900646A patent/EA015108B1/ru not_active IP Right Cessation
- 2005-12-23 PL PL08165631T patent/PL2033629T3/pl unknown
- 2005-12-23 RS RS20120564A patent/RS52607B/sr unknown
- 2005-12-23 SI SI200531638T patent/SI2033629T1/sl unknown
- 2005-12-23 US US11/794,039 patent/US20080102120A1/en not_active Abandoned
- 2005-12-23 CN CN2005800447851A patent/CN101087589B/zh not_active Expired - Fee Related
- 2005-12-23 ES ES08165631T patent/ES2397552T3/es not_active Expired - Lifetime
- 2005-12-23 EA EA200701107A patent/EA012392B1/ru not_active IP Right Cessation
- 2005-12-23 PT PT81656316T patent/PT2033629E/pt unknown
- 2005-12-23 EP EP08165631A patent/EP2033629B1/en not_active Revoked
- 2005-12-23 AU AU2005318365A patent/AU2005318365B2/en not_active Ceased
- 2005-12-23 EP EP20050824409 patent/EP1833464A1/en not_active Withdrawn
- 2005-12-23 WO PCT/EP2005/013963 patent/WO2006066961A1/en not_active Ceased
- 2005-12-23 DK DK08165631.6T patent/DK2033629T3/da active
- 2005-12-23 ME MEP-2012-149A patent/ME01453B/me unknown
- 2005-12-23 CA CA002592091A patent/CA2592091A1/en not_active Abandoned
2007
- 2007-07-24 NO NO20073889A patent/NO20073889L/no not_active Application Discontinuation
2013
- 2013-01-16 HR HRP20130033TT patent/HRP20130033T1/hr unknown

Also Published As

Publication number	Publication date
ME01453B (me)	2014-04-20
AU2005318365B2 (en)	2011-02-03
EP2033629B1 (en)	2012-11-14
EP2033629A1 (en)	2009-03-11
AU2005318365A1 (en)	2006-06-29
EP1833464A1 (en)	2007-09-19
CA2592091A1 (en)	2006-06-29
EA015108B1 (ru)	2011-06-30
EA012392B1 (ru)	2009-10-30
DK2033629T3 (da)	2013-02-04
ES2397552T3 (es)	2013-03-07
US20080102120A1 (en)	2008-05-01
EA200900646A1 (ru)	2009-10-30
HRP20130033T1 (hr)	2013-02-28
RS52607B (sr)	2013-04-30
WO2006066961A1 (en)	2006-06-29
CN101087589A (zh)	2007-12-12
EA200701107A1 (ru)	2008-04-28
CN101087589B (zh)	2013-01-30
PT2033629E (pt)	2013-01-24
NO20073889L (no)	2007-09-24
SI2033629T1 (sl)	2013-01-31

Publication	Publication Date	Title
IL223545A0 (en)	2013-02-03	Pharmaceutical compositions
ZA200700030B (en)	2009-06-24	Pharmaceutical compositions
IL177480A0 (en)	2006-12-10	Pharmaceutical composition
GB0408308D0 (en)	2004-05-19	Pharmaceutical compositions
IL186336A0 (en)	2008-01-20	Pharmaceutical composition
IL183986A0 (en)	2007-10-31	Pharmaceutical compounds and compositions
ZA200705131B (en)	2008-06-25	Solid pharmaceutical composition comprising valsartan
SI2033629T1 (sl)	2013-01-31	Trden farmacevtski sestavek, ki obsega valsartan
PL1837019T3 (pl)	2013-02-28	Kompozycja farmaceutyczna rozpadająca się w ustach
HU0401177D0 (en)	2004-08-30	Pharmaceutical composition
GB2411355B (en)	2006-02-22	Pharmaceutical composition
EP1805154A4 (en)	2009-11-25	PHARMACEUTICAL COMPOSITIONS
GB0425255D0 (en)	2004-12-15	Pharmaceutical composition
ZA200701932B (en)	2008-08-27	Pharmaceutical composition
ZA200700844B (en)	2009-07-29	Quinolone-containing medicinal composition
ZA200701931B (en)	2008-10-29	Pharmaceutical composition
GB0407351D0 (en)	2004-05-05	Pharmaceutical compositions
GB0400971D0 (en)	2004-02-18	Pharmaceutical compositions
GB0502792D0 (en)	2005-03-16	Pharmaceutical compositions
GB0411502D0 (en)	2004-06-23	Pharmaceutical compositions
GB0402799D0 (en)	2004-03-10	Pharmaceutical composition
GB0425259D0 (en)	2004-12-15	Pharmaceutical composition
GB0425256D0 (en)	2004-12-15	Pharmaceutical composition
GB0425728D0 (en)	2004-12-22	Pharmaceutical compositions
GB0412733D0 (en)	2004-07-07	Pharmaceutical compositions